PMID- 27163676
OWN - NLM
STAT- MEDLINE
DCOM- 20170705
LR  - 20190219
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 11
IP  - 5
DP  - 2016
TI  - Effect of Pioglitazone in Preventing In-Stent Restenosis after Percutaneous 
      Coronary Intervention in Patients with Type 2 Diabetes: A Meta-Analysis.
PG  - e0155273
LID - 10.1371/journal.pone.0155273 [doi]
LID - e0155273
AB  - BACKGROUND: The benefits of pioglitazone in patients with type 2 diabetes 
      mellitus (T2DM) after percutaneous coronary intervention (PCI) is unclear. 
      OBJECTIVES: To evaluate the effect of pioglitazone on prevention of in-stent 
      restenosis (ISR) in patients with T2DM after PCI. METHODS: All full-text 
      published relevant studies compared the effect of pioglitazone with control group 
      (placebo or no pioglitazone treatment) on ISR in patients with T2DM after PCI 
      were identified by searching the databases including PubMed, EMBASE, Cochrane 
      Library and ISI Web of Science through October 2015. The endpoints were defined 
      as the rate of ISR, late lumen loss, in-stent neointimal volume, target lesion 
      revascularization (TLR) and major adverse cardiac events (MACE). RESULTS: Six 
      studies (5 RCTs and 1 retrospective study), comprising 503 patients, were 
      included into this meta-analysis. In the pioglitazone group, as compared with the 
      control group, the risk ratio for ISR was 0.48 (I2 = 14.5%, P = 0.322; 95%CI 0.35 
      to 0.68, P<0.001), the risk ratio for TLR was 0.58 (I2 = 6.0%, P = 0.363; 95%CI 
      0.38 to 0.87, P = 0.009). The result showed there was no association between the 
      use of pioglitazone and the events of MACE (I2 = 36.7%, P = 0.209; RR 0.56, 95%CI 
      0.30 to 1.05, P = 0.071). For the considerable heterogeneity, further analysis 
      was not suitable for the endpoints of late lumen loss (I2 = 81.9%, P<0.001) and 
      neointimal volume (I2 = 75.9%, P = 0.016). CONCLUSIONS: The treatment of 
      pioglitazone was associated with a reduction in ISR and TLR in T2DM patients 
      suffering from PCI, except the incidence of MACE.
FAU - Zhao, Shi-Jie
AU  - Zhao SJ
AD  - Department of Geriatric Cardiology, First Affiliated Hospital, China Medical 
      University, Shenyang, China.
FAU - Zhong, Zhao-Shuang
AU  - Zhong ZS
AD  - Department of Respiratory, Central Hospital, Shenyang Medical College, Shenyang, 
      China.
FAU - Qi, Guo-Xian
AU  - Qi GX
AD  - Department of Geriatric Cardiology, First Affiliated Hospital, China Medical 
      University, Shenyang, China.
FAU - Shi, Li-Ye
AU  - Shi LY
AD  - Department of Geriatric Cardiology, First Affiliated Hospital, China Medical 
      University, Shenyang, China.
FAU - Chen, Ling
AU  - Chen L
AD  - Department of Geriatric Cardiology, First Affiliated Hospital, China Medical 
      University, Shenyang, China.
FAU - Tian, Wen
AU  - Tian W
AD  - Department of Geriatric Cardiology, First Affiliated Hospital, China Medical 
      University, Shenyang, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20160510
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Thiazolidinediones)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Aged
MH  - Angioplasty, Balloon, Coronary
MH  - Coronary Angiography
MH  - Coronary Occlusion/complications/diagnostic imaging/*drug therapy/surgery
MH  - Coronary Restenosis/etiology/pathology/*prevention & control
MH  - Coronary Vessels/diagnostic imaging/pathology/surgery
MH  - Diabetes Mellitus, Type 2/complications/diagnostic imaging/*drug therapy/surgery
MH  - Drug Administration Schedule
MH  - Drug-Eluting Stents/*adverse effects
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Middle Aged
MH  - Pioglitazone
MH  - Retrospective Studies
MH  - Risk
MH  - Thiazolidinediones/*therapeutic use
MH  - Treatment Outcome
PMC - PMC4862640
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2016/05/11 06:00
MHDA- 2017/07/06 06:00
PMCR- 2016/05/10
CRDT- 2016/05/11 06:00
PHST- 2015/12/21 00:00 [received]
PHST- 2016/04/26 00:00 [accepted]
PHST- 2016/05/11 06:00 [entrez]
PHST- 2016/05/11 06:00 [pubmed]
PHST- 2017/07/06 06:00 [medline]
PHST- 2016/05/10 00:00 [pmc-release]
AID - PONE-D-15-50201 [pii]
AID - 10.1371/journal.pone.0155273 [doi]
PST - epublish
SO  - PLoS One. 2016 May 10;11(5):e0155273. doi: 10.1371/journal.pone.0155273. 
      eCollection 2016.